An expert panel of India’s central drug authority granted regular market approval to Covid vaccines Covishield and Covaxin. A market authorisation label for a vaccine means it can be authorised for use without reservations or conditions.
Both SII and Bharat Biotech confirmed that and an approval has come in from the subject expert committee (SEC).
Central Drugs Standard Control Organisation (CDSCO) also took to Twitter to confirm that its “SEC has recommended for upgrade of Covishield and Covaxin status from restricted use in emergency situations to grant of new drug permission with conditions in the adult population, DCGI will evaluate the recommendations and give its decision.”
“The Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) which reviewed SII and Bharat Biotech’s application for the second time on Wednesday has recommended granting regular market approval to Covishield and Covaxin subject to certain conditions,” an official source told news agency PTI said.
Speaking on how these vaccines will be marketed, a source mentioned that it will be available at clinics and hospitals registered with CoWin. At the time of administration, the clinic/hospital will put in details in CoWIN.
Pharma companies Serum Institute of India (SII) and Bharat Biotech had submitted applications to the Drugs Controller General of India (DCGI) seeking regular market authorisation for their respective Covid-19 vaccines Covishield and Covaxin.
Prakash Kumar Singh, director (government and regulatory affairs) at SII, had submitted an application to the DCGI on October 25 on this matter.
On that, DCGI had sought more data and documents from the Pune-based company following which Singh recently submitted a response along with more data and information.
In addition to the successful completion of phase 2/3 clinical study in India, till now, more than 100 crore doses of Covishield vaccine have been administered to the people of this country and worldwide, Singh is learnt to have stated in the response.
“Such a large-scale vaccination with Covishield and containment of Covid-19 infection is in itself a testimony of the safety and efficacy of the vaccine,” he had said.
In an application sent to the DCGI a couple of weeks ago, V Krishna Mohan, whole-time director at the Hyderabad-based company, submitted complete information regarding chemistry, manufacturing and controls, along with the pre-clinical and clinical data while seeking regular market authorisation for Covaxin.
Bharat Biotech International Limited (BBIL) took up the challenge to develop, produce and clinically evaluate a vaccine (Covaxin), from the SARS-CoV-2 strains isolated from COVID-19 patients in India, Mohan had said in the application.
Covaxin and Covishield were granted Emergency Use Authorisation (EUA) on January 3. PTI